The foundation of first-trimester preeclampsia screening rests on two well-validated maternal serum markers: Pregnancy-Associated Plasma Protein-A (PAPP-A) and Placental Growth Factor (PlGF). These analytes are the biochemical core of immunoassay panels designed to assess risk before 14 weeks of gestation. When their concentrations are interpreted alongside maternal characteristics and biophysical measurements, the resulting algorithm can flag the majority of women destined to develop the severe, early-onset form of the disease.
The definitive first-trimester biochemical panel for preeclampsia risk is built around PAPP‑A and PlGF. Additional angiogenic and anti‑angiogenic factors—such as sFlt‑1, soluble endoglin, activin A, and inhibin A—are subjects of research and later‑stage triage assays but are not the primary drivers of first‑trimester screening algorithms.
The Core Biochemical Markers in First‑Trimester Screening
The best‑performing first‑trimester preeclampsia screening models combine maternal history, biophysical parameters, and a targeted set of serum proteins that reflect placental development. Two markers consistently emerge as the biochemical pillars.
Pregnancy‑Associated Plasma Protein‑A (PAPP‑A): A Marker of Placentation
PAPP‑A is a protease that regulates insulin‑like growth factor bioavailability, a process critical for trophoblast invasion and spiral artery remodeling.
In pregnancies destined for preeclampsia, first‑trimester PAPP‑A concentrations are reduced, signaling impaired placentation long before clinical symptoms appear.
This drop is most pronounced in early‑onset cases, where defective remodeling of the uterine arteries is the initiating pathology.
Placental Growth Factor (PlGF): An Angiogenic Sentinel
PlGF is a pro‑angiogenic protein produced by the placental syncytiotrophoblast. It plays a key role in maintaining a healthy, well‑perfused vascular interface at the maternal‑fetal boundary.
In the first trimester, low serum PlGF reflects an already‑dysfunctional placenta that is failing to establish the necessary low‑resistance circulation.
Because PlGF concentration is closely linked to the angiogenic balance, its early decline provides a direct functional readout of the vascular maladaptation central to preeclampsia.
Beyond the Core: The Angiogenic‑Antiangiogenic Axis
A wider set of placental factors has been studied for diagnostic and monitoring immunoassays. Their primary utility, however, lies in later pregnancy or as adjuncts to first‑trimester risk refinement.
Soluble fms‑Like Tyrosine Kinase‑1 (sFlt‑1) and Soluble Endoglin
sFlt‑1 is an anti‑angiogenic trap that binds PlGF and VEGF, creating a systemic endothelial dysfunction.
Its rise is a hallmark of established preeclampsia, but first‑trimester alterations are less consistent, making sFlt‑1 more useful in triage (e.g., the sFlt‑1/PlGF ratio for rule‑out at 24–36 weeks) than in early screening panels.
Similarly, soluble endoglin amplifies the anti‑angiogenic state. While it contributes to the disease mechanism, it has not displaced PAPP‑A and PlGF as a first‑trimester cornerstone.
Other Studied Factors (Activin A, Inhibin A)
Activin A and inhibin A are placental glycoproteins linked to trophoblast differentiation and immune tolerance.
They show altered maternal serum levels in preeclamptic pregnancies and have been evaluated in research‑grade multiplex assays.
Currently, these markers are not standard components of first‑trimester screening kits, as their incremental benefit over PAPP‑A and PlGF is not yet proven in large‑scale algorithms.
The Predictive Power of Integrated Algorithms
It is the compound effect of biochemical, biophysical, and maternal data—not any single marker—that delivers the high detection rates cited in clinical studies.
Combining Biochemistry with Biophysics
When PAPP‑A and PlGF immunoassay results are combined with mean arterial pressure and uterine artery pulsatility index, the screening performance leaps.
These biophysical signs add orthogonal information: they capture the hemodynamic consequences of poor placentation, reinforcing the biochemical signal.
The result is a multi‑factorial risk score that outperforms any individual parameter.
Targeting Early‑Onset Disease
The primary reference shows that such integrated first‑trimester panels can identify up to 90% of women who will develop early‑onset preeclampsia (before 34 weeks).
This is achieved at a 5% false‑positive rate, a threshold that makes prophylactic intervention with low‑dose aspirin both clinically and economically acceptable.
The detection rate is substantially higher for early‑onset disease than for late‑onset disease, which is often driven more by maternal constitutional factors than by a primary placental insult.
Understanding the Limitations and Trade‑offs
No screening panel is perfect, and developers must navigate several inherent constraints when designing assays.
Early‑onset vs. late‑onset sensitivity. The same PAPP‑A‑PlGF algorithm may miss a significant number of late‑onset preeclampsia cases, where placental biomarkers deviate less profoundly in the first trimester.
Marker variability. PAPP‑A and PlGF levels are influenced by maternal weight, ethnicity, smoking, and conception mode—necessitating careful adjustment of multiples of the median (MoM) values.
Threshold ambiguity. Establishing population‑specific cut‑offs requires large, diverse cohorts, and small calibration errors can shift false‑positive rates.
False‑positive burden. Even at 5%, false screening positives create anxiety and may lead to unnecessary surveillance. Balancing sensitivity with patient‑centered care demands rigorous assay precision.
A Blueprint for Diagnostic Kit Development
For IVD manufacturers building first‑trimester preeclampsia screening panels, success hinges on selecting the right analytes and ensuring robust analytical performance.
After a brief introductory sentence, the following goal‑based recommendations pinpoint where to focus effort:
- If your primary focus is early‑onset preeclampsia detection: Anchor your panel on PAPP‑A and PlGF, and pair them with integrated algorithm support that accepts biophysical inputs.
- If your primary focus is a comprehensive maternal‑fetal screening platform: Add the sFlt‑1/PlGF ratio as a second‑trimester rule‑out module, but keep the first‑trimester engine centered on the PAPP‑A/PlGF duo.
- If your primary focus is differentiating preeclampsia from gestational hypertension: Explore activin A, inhibin A, or soluble endoglin as secondary markers in a reflex testing cascade, while understanding that they currently lack the evidence base of the core pair.
- If your primary focus is kit robustness and regulatory clearance: Source high‑purity recombinant antigens and well‑characterized monoclonal antibodies against PAPP‑A and PlGF, as these are the most proven, guideline‑endorsed targets.
A disciplined approach that builds from the PAPP‑A‑PlGF core while thoughtfully evaluating adjunct markers will produce the most clinically valuable and commercially viable assay—one that truly helps clinicians rewrite the trajectory of preeclampsia.
Summary Table:
| Marker | Biological Function | First-Trimester Trend | Assay Role & Status |
|---|---|---|---|
| PAPP-A | Regulates IGF bioavailability for trophoblast invasion | Significantly Reduced | Core Biomarker (Primary screening algorithms) |
| PlGF | Pro-angiogenic factor for placental vascular integrity | Low | Core Biomarker (Primary screening algorithms) |
| sFlt-1 | Anti-angiogenic protein that binds PlGF/VEGF | Variable / Inconsistent | Secondary (2nd/3rd trimester triage & sFlt-1/PlGF ratio) |
| Soluble Endoglin | Amplifies anti-angiogenic endothelial dysfunction | Inconsistent | Adjunct research target |
| Activin A / Inhibin A | Glycoproteins involved in trophoblast differentiation | Altered | Evaluated in research multiplex panels |
Developing next-generation first-trimester preeclampsia screening panels?
CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials—including recombinant antigens and monoclonal antibodies for PAPP-A, PlGF, and sFlt-1—along with comprehensive technical services and consulting, covering every stage from concept to clinic.
Contact us today to optimize your assay performance and accelerate your diagnostic pipeline!